Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.
Primary 1. To evaluate the achievement of NEDA using blood and CSF neurofilaments in Alemtuzumab treated patients. Secondary 2. To assess prognosis at the end of the study based on neurofilament status. 3. To correlate neurofilament levels with clinical and MRI markers of disease activity. 4. To evaluate the effect of Alemtuzumab on the profile of other CSF, blood, urine, faeces biomarkers of inflammation, neurodegeneration, neuronal sprouting and synaptogenesis, treatment activity and metabolic activity.
Study Type
OBSERVATIONAL
Enrollment
21
Licensed dose
Queen Mary University of London
London, England, United Kingdom
Blood and CSF neurofilaments in Alemtuzumab patients over 24months
Neurofilaments
Time frame: 2 years
Overall clinical response based on neurofilament response
neurofilaments
Time frame: 2 years
Neurofilament status and association with clinical and MRI markers of disease activity.
Correlation index
Time frame: 2 years
Longitudinal assessment of other biomarkers of inflammation & plasticity
Correlation index
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.